The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative.

DSpace/Manakin Repository

The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative.

Show simple item record

dc.contributor.author Bessone, Fernando.
dc.contributor.author Hernandez, Nelia.
dc.contributor.author Lucena, Isabel.
dc.contributor.author Andrade, Raul.
dc.contributor.author Piñero, Federico.
dc.contributor.author Mendizabal, Manuel.
dc.date.accessioned 2020-03-06T17:29:22Z
dc.date.available 2020-03-06T17:29:22Z
dc.date.issued 2016-02-25
dc.identifier.citation Int J Mol Sci. 2016 Feb 29;17(3):313 en_US
dc.identifier.issn 1661-6596
dc.identifier.uri https://riu.austral.edu.ar/handle/123456789/860
dc.description.abstract Drug induced liver injury (DILI) is a rare but well recognized serious adverse reaction. Pre-marketing studies may not detect liver injury, and DILI becomes very often apparent after the drug is launched to the market. Specific biomarkers for DILI prediction or diagnosis are not available. Toxic liver reactions present with a wide spectrum of phenotypes and severity, and our knowledge on the mechanisms underlying idiosyncratic reactions and individual susceptibility is still limited. To overcome these limitations, country-based registries and multicenter research networks have been created in Europe and North America. Reliable epidemiological data on DILI in Latin America (LA), a region with a large variety of ethnic groups, were however lacking. Fortunately, a LA network of DILI was set up in 2011, with the support of the Spanish DILI Registry from the University of Malaga. The primary aim of the Latin DILI Network (LATINDILIN) Registry was to prospectively identify bona fide DILI cases and to collect biological samples to study genetic biomarkers. Physicians involved in the project must complete a structured report form describing the DILI case presentation and follow-up which is submitted to a Coordinator Center in each country, where it is further assessed for completeness. During the last four years, several LA countries (Argentina, Uruguay, Chile, Mexico, Paraguay, Brazil, Ecuador, Peru, Venezuela and Colombia) have joined the network and committed with this project. At that point, to identify both our strengths and weaknesses was a very important issue. In this review, we will describe how the LATINDILI Registry was created. The aims and methods to achieve these objectives will be discussed in depth. Additionally, both the difficulties we have faced and the strategies to solve them will be also pinpointed. Finally, we will report on our preliminary results, and discuss ideas to expand and to keep running this network. en_US
dc.language.iso en en_US
dc.publisher MDPI en_US
dc.subject Latin-American DILI registry en_US
dc.subject Spanish DILI registry en_US
dc.subject Drug-induced liver injury en_US
dc.subject Hepatotoxicity en_US
dc.subject Herbals and dietary supplements en_US
dc.title The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. en_US
dc.type Article en_US


Files in this item

Files Size Format View Description
Int J Mol Sci. 2016 Feb 29;17(3);313..pdf 554.2Kb PDF View/Open IA - Bessone

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account